

Invitation to presentation of Xbrane Biopharma's interim report January – March 2020 on May 13, 2020.

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on May 13, 2020, at 16.00 a.m. CET. Xbrane will publish the Company's interim report January – March 2020, on Wednesday May 13, 2020, at 8.00 a.m. CET.

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the interim report January – March 2020, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 338
UK (Local): +44 (0) 844 481 97 52
UK (Tollfree): 08 002 796 619
Sweden (Local): +46 (0) 850 692 180
Sweden (Toll Free): 020 012 51 60
US (Local): +1 646 741 31 67
US (Toll Free): +1 877 870 91 35
Confirmation Code: 18 56 899

Web link:

<https://edge.media-server.com/mmc/p/aniha5nx>

Contacts

Martin Åmark, CEO/ IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.

Press Release
13 May 2020 08:00:00 CEST



Attachments

[Invitation to presentation of Xbrane Biopharma's interim report January – March 2020 on May 13, 2020.](#)